Orange Book product · Generic (ANDA)
VIGABATRIN
VIGABATRIN
At a glance
May 10, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 10, 2022
4 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
VIGABATRIN
Strength
500MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 215601
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of VIGABATRIN
- 2024VIGAFYDEBrand (NDA)
NDA 217684 · PYROS PHARMS
- 2009SABRILBrand (NDA)
NDA 022006 · LUNDBECK PHARMS LLC
- 2009SABRILBrand (NDA)
NDA 020427 · LUNDBECK PHARMS LLC
- 2023VIGABATRINGeneric (ANDA)
ANDA 214749 · UPSHER SMITH LABS
- 2023VIGABATRINGeneric (ANDA)
ANDA 215519 · CARNEGIE
- 2023VIGABATRINGeneric (ANDA)
ANDA 214671 · ZYDUS LIFESCIENCES
- 2022VIGABATRINGeneric (ANDA)
ANDA 215363 · MSN
- 2022VIGABATRINGeneric (ANDA)
ANDA 213104 · HIKMA
- 2022VIGPODERGeneric (ANDA)
ANDA 214961 · PYROS PHARMS
- 2022VIGABATRINGeneric (ANDA)
ANDA 210042 · AMNEAL PHARMS
- 2022VIGABATRINGeneric (ANDA)
ANDA 211790 · CHARTWELL RX
- 2022VIGABATRINGeneric (ANDA)
ANDA 215707 · ZYDUS LIFESCIENCES
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
